Navamedic ASA: Double Digit Growth in the 3rd Quarter, 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, reported a 12.9% increase in revenues to NOK 138.9 million in the third quarter of 2025.
Gross margin improved to 37.5% compared to 37.1% in Q3 2024, and Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
The revenue growth was driven by increases in all three business areas, with the Rx business area including NOK 10.6 million in revenues from the dne business.
No additional statements were provided.
Author's summary: Navamedic ASA reports 12.9% revenue growth.
More News
- Mercor Capitalizes on Industry Upheaval, Reaches $10 Billion Valuation with $350 Million Funding Surge
- The Most Dazzling Looks From The Angel Ball's 2025 Red Carpet
- TikTok U.S. Creator Summit: Three new features announced today - 9to5Mac
- The Angel Ball Honors Tina Knowles
- Tomago Aluminium is more than just a smelter, it's a strategic asset
- Travel-Ready Base Layers That Simplify Packing
- NYC Selects Rybak as Developer for Coney Island Housing Project
- Where to Kill a Buck This Weekend: Target These Key Food Sources and Scrapes